Skip to main content
Cannara Biotech Inc. logo

Cannara Biotech Inc. — Investor Relations & Filings

Ticker · LOVE LEI · 875500MHKAAYHYVYZ941 TSXV Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2026-04-14 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV LOVE

About Cannara Biotech Inc.

https://www.cannara.ca/

Cannara Biotech Inc. is a vertically integrated producer specializing in the cultivation and sale of premium-quality cannabis and cannabis-derivative products for the Canadian recreational and medical markets. The company operates state-of-the-art indoor cultivation facilities spanning over 1,650,000 square feet, designed for high efficiency, sustainability, and low-cost production, with an annualized output capacity of up to 100,000 kg. Cannara offers a wide range of products, including dried flowers, pre-rolls, and oils, marketed under brands such as TRIBAL, nugz, and ORCHID CBD. The company leverages advanced cultivation techniques and scale to deliver consistent, high-quality products at competitive value.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive set of 'Condensed Interim Consolidated Financial Statements' for Cannara Biotech Inc. for the three and six-month periods ended February 28, 2026. It includes the Statement of Financial Position, Statement of Net Income, Statement of Changes in Equity, Statement of Cash Flows, and detailed notes to the financial statements. This meets the criteria for an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. H1 2026
2026-04-14 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing an updated Mineral Resource Estimate under NI 43-101 guidelines for the Gaspé Copper Project. It contains detailed geological and resource tables, drill program plans, and technical parameters. It is not an earnings release, annual or quarterly report, financing or AGM material, nor a dividend or voting notice. It is a general operational/regulatory news announcement filed on TSX/OTCQX, so it best fits the fallback category for miscellaneous regulatory filings (RNS).
2026-04-14 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Cannara Biotech Inc. for the three and six-month periods ended February 28, 2026. It contains comprehensive financial statements (Statement of Financial Position, Statement of Net Income, Statement of Changes in Equity, Statement of Cash Flows) and detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2026
2026-04-14 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is a standalone Management Discussion & Analysis (MD&A) for the three and six-month periods ended February 28, 2026. It contains forward-looking statements, non-GAAP measures, segment analyses and detailed management commentary on financial performance and outlook, without presenting the full interim consolidated financial statements. This corresponds to “Management Reports” (MDA) rather than a full Interim Report (IR) or just an announcement. Therefore, the correct classification is MDA.
2026-04-14 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a certification form (Form 52-109FV2) by the CFO attesting to the review and fair presentation of the interim financial report and MD&A for the period ended February 28, 2026. It is not the interim report itself (which would fall under “Interim / Quarterly Report (IR)”), nor is it announcing or summarizing financial results. Instead, it is a standalone regulatory certificate filed under Canadian NI 52-109 for venture issuers, making it a general regulatory filing. Therefore, it is best classified as a Regulatory Filing (RNS).
2026-04-14 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the CFO under Canadian NI 52-109 for a venture issuer’s interim period ended February 28, 2026. It is not the interim financial report or MD&A itself, but a statutory certificate confirming the accuracy of those filings. This is a regulatory compliance submission rather than an actual interim report, presentation, or other specified category, so it falls under the fallback “Regulatory Filings” category.
2026-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.